| (Values in U.S. Thousands) | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 | Dec, 2025 |
| Sales | 12,940 | 9,600 | 13,370 | 14,160 | 0 |
| Sales Growth | +34.79% | -28.20% | -5.58% | unch | unch |
| Net Income | -43,560 | -77,310 | -54,610 | -43,930 | 0 |
| Net Income Growth | +43.66% | -41.57% | -24.31% | unch | unch |
Sigilon Therapeutics Inc (SGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Sigilon Therapeutics Inc. is a biotechnology company. It seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics(TM) platform. The company's product candidates consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, diabetes and lysosomal storage disorders. Sigilon Therapeutics Inc. is based in CAMBRIDGE, Mass.
Fiscal Year End Date: 12/31